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(F) additionaly in Phase I11 (C + G + A/S + F). 92 cases in 48 
de novo Ah4L patients were enrolled from 17 center. 26 cases were 
excluded h m  the analysis. The efficacy of this trial was evaluated in 
66 cases. 
Results (see table): Total response rate was 79%. The response 
rate was also analysed by patients with fever of unknown origin (n = 
28), response rate = 82%; clinically documented infections (n = 25) 
- 80%; microbiologically documented infections (n = 7) - 57%. 
Conclusions: Ampicillin/Sulbactam and Fluconazole can be used 
by empirical treatment of febrile neutcopenic patients. 
lp13461 Randomised Prospective Comparative Study of 
Cefepime (CEF) and Ceftaridime (CAZ) in 
Combination with Amikacin (AM) in the 
Treatment of Febrile Neutropenia 
G. Petrikkos ' , M. Bourlakis ' , V Seitanides ', A. Kousoulakou ', 
E. Giannitsioti', A. Toskas', H. Giamarellou'. 'Laiko General 
Hospital, Athens, Greece, 'Mefuxa Cancer Hospifal, Pirueuz, Greece 
Objective: To evaluate the efficacy of CEF CAZ plus AM in the 
treatment of patients with febrile neutropenia (PMN 5500/mm3). 
Methods: In an ongoing, randomized, prospective, comparative 
study CEF and CAZ were given at a dose of 2 g TID IV in combi- 
nation with AM (15 mg/kg OD IV). Out of 68 randomized patients 
(33 men, 35 women), 35 (x age 57 y) in CEF group and 33 (x 
age 53.2 y patients) in the CAZ group were assessed. Most of the 
patients, 21 (60%) in the CEF and 23 (70%) in the CAZ group were 
suffering fkm acute leukemia while 7 (20%) and 11 (35%) respec- 
tively were severe neutropenics (PMN t100/mm3). Sixteen (46%) 
patients in the CEF group and 21 (64%) patients in the CAZ group 
were presented with FUO while 19 (54%) and 12 (36%) patients 
respectively had clinically or microbiologically documented mfec- 
tions. Four bacteremias in the CEF and 7 in the CAZ group were 
documented. 
Results: The success rates in the CEF and CAZ group were 
62% and 81% of the FUO cases while in cases with chnically or 
microbiologically documented infection the success rates mounted 
51% and 44% respectively. 
Conclusions: From the up to now results CEF in combination 
with AM seems to be equally effective with CAZ plus AM in the 
treatment of febrile neutropenia. 
[p1347] Economic Impact of Bacteremia in Neutropenic 
N. Rivas, C. Hascalovici, W Dobranski, D. Ricchione, 
M.M. Contrini, E.L. L6pez. Hospital de Nirios "R. GutiCrrez", 
Buenos A i m ,  Argentina 
No data are available about direct cost in NC with bacteremia. Our 
study analyzed Werent variables related the cost-impact in the man- 
agement ofthis pathology. From Jan 1994-Dec 1996 we studied 264 
febrile episodes in 142 patients. Bacteremias 391264 (14.7%) Pri- 
mary Bacteremia (PB) (Positive blood cultures before the 5* day 
of admission) 31 (79.5%) Secondary bacteremia (SB) 8 (20.5%). We 
considered SB as nosocomial infection (NI) being 8/23 (34.8%) vs 
NI without bacteremia 15/23 (65.2%) p = 0.01. The x hospital stay 
in PB was: x SD 18.8 & 9 vs. 36.6 f 18.5 days in SB. We found 
no difference between bacteremias by Gram (+) and Gram (-) or- 
ganism; 18.6 vs. 18.2 days respectively; fungemia was 31.5 days in 
PB. vs. 38.6 in SB. The total cost of PB, was u& 4.384, 65 vs. u9s 
10.127, 10 in SB. Fungemia treatment costs was uSs 7.294. Our hos- 
pital day value is uts 200; the final impact-cost of this variable was 
83.1% in PB and 75.4% in SB. Antimicrobial therapy represented 
Children (NC) with Malignancies in Argentina 
16.9% and 24.6% in PB and SB respectively. In final cost G-CSF 
treatment represented a 72.1% in PB vs. 16.8% in SB. 
Conclusions: The main variable impact cost was the hospital stay. 
No differences were found between Merent organism in PB. In the 
global cost SB was 130% higher than PB. 
I P1348 I Anergy to Micobacterial Antigens in Lung 
Cancer Patients 
D.A. Chemoshey, L.P. Titov. Minsk Medical Institute, Minsk, Belarus 
Skin tests are widely used to evaluate the immune response in a 
range of pathological conditions that is characterized by an immun- 
odepression. The intraskin immune response (such as Mantaux re- 
action) development includes such stages as: antigen presentation, 
Thl subset cells and T effectors generation, sertain cytokines' genes 
expression and allow to evaluate only the ability of immune system 
to answer cemin stimuiy in a proper way whereas present level of 
knowledge of immunogenesis demands more precise determination 
of disturbances level. 
Objectives: ofthe paper were to study the hypoimmunoreactivity 
of lung cancer patients to micobacterial antigens and to search the 
way for the condition correction. 
Materials and Methods: the modified skin tests were performed 
in 50 lung cancer patients (epidermoid cancer and adenocarcinoma, 
11-111 stage). The antigen (EPPD (5T), PPD + Theophylline (16 
mkg), PPD + Cyclosporine A (0.625 mkg)) was introduced into the 
forearm slun in the volum of 0.1 ml. 
Results: The results were obtained in 72 h. by measuring of 
maximum infiltration dimensions. Anergy to micobacterial antigens 
was determined in 48% patients examined. The data about local in 
vivo correction are given in Table 1. 
Table 1. The intensity oflung cancer pincnn response in modttied rkm tests in the depen- 
dence ofiniud answer to PPD (mfimtion diimetcrr. mm) 
antigen Controls Lung cancer patienn (n = 50) 
(n = 10) 
anergy nodhyperergy 
- PPD 7.50 f 0.88 6.88 f 0.49 
PPD + Th 10.33 f 0.84 1.63 f 0.50 8.00 f 1.10 
PPD + Cr 14.50 f 0.96- 7.00 f 1.36** 8.50 f 1.75 
*-difference IS rehablc between answer to PPD 2nd PPD f Cs (p < 0.05) 
dfference IS rcliable between answer to PPD i Th and PPD f Cr (p -z 0.05) *(I 
Conclusions: 1. Slun tests revealed severe damage of cellular an- 
swer to PPD (anergy) in 48% lung cancer patients; 2. Theophylline 
and Cyclosporine A in appropriate dose can be concidered as po- 
tential local immunocorrectors (both of them can abolish the anergy 
condition in 25%-30% cases). 
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I P1349 I Seronegativity to Human Herpesvirus 6 is a 
Risk Factor for lnvasive Fungal Infection Post 
Liver Transplantation 
D. Dockrell, M. Jones, A. Badley, W Harmsen, D. Ilstrup, T. Smith, 
R. Wiesner, R. Krom, C. Pap. Muyo Clinic, Rochestq Minnesota, 
USA 
Invasive fungal infection has a major impact on the morbidity and 
mortality of liver transplant recipients. Identification of underly- 
ing risk factors for hs infectious complication enable the design 
of preventative measures. Human herpesvirus-6 (HHV-6) has been 
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associated with increased immunosuppression in immunocompro- 
mised hosts. We therefore examined whether pretransplant HHV-6 
seronegativity was a risk factor for posttransplant fungal infection. 
Pretransplant sera from 247 transplant recipients analyzed for IgG 
to HHV-6 using indirect immunofluorescence identified 33 (13%) 
HHV-6 seronegative recipients. Six of 33 (18%) seronegative re- 
cipients experienced fungal dection compared to 15 of 214 (7%) 
seropositive recipients. In a univariate analysis of risk factors for fun- 
gal infection in the first 90 days posttransplantation the following 
were identified as sigdicant risk factors: pretransplant seronegativ- 
ity to HHV-6 (p = 0.034), intraoperative cryoprecipitate require- 
ments greater than the 75th percende (p = 0.035), reoperation (p 
= 0.005), biliary stricturing postoperatively (p = 0.046) and GI or 
vascular complications postoperatively (p = 0.030). CMV disease 
was only of borderline significance (p = 0.087). Multivariate anal- 
ysis was performed with each of the sipficant variables combined 
pairwise with HHV-6 seronegativity. Pretransplant HHV-6 seroneg- 
ativity remained a signbcanc variable even in the presence of the 
other variables. These results suggest that HHV-6 seronegativity pre- 
transplant is a sigmficant risk factor for fungal dection in the first 
90 days posttransplantation. 
in 43.1%: Non-albicans Candida spp. (C. stellatorden, C. krusei, C. 
tropicalis, C. parapsilosir) in 8 .  Non-Candida spp. yeasts (Trichosporon 
(7’) beigelii, ?: pullulans, Tomlopsis glabrata, G laurentii, Hansenula 
anomala, Rhodotomla mbra, Blastoschizomyces capitafus) appeared in 14 
and molds (Mutor spp., Fusarium spp.) were isolated from blood cul- 
tures in 3 patient. Analyzing etiology of isolates either from blood 
cultures or &om non-sterile body Utes, no shift in 1989-1995 was 
observed 68.1% were C. albicans, 20.5% Non-albicans Candida spp., 
5.9% Non-Candida yeasts and 1.8% molds and remained stable in all 
observed period. 
} P1352 1 Breakthrough Fungemia in 12 Cancer Patients 
Occurring During Empiric Therapy with AmB 
S. Spanik, J. Trupl, A. Kunova, K. Kralovicova, Z. Jesenska, 
Y. Krupova, V. Krcmery, Jr.. Dept. ofMedin’ne, Univenity of Trnava, 
Tmava, Slovak Republic, Dept. of Pharmacology, St. Elizabeth Cancer 
Institute, Bratislava, Slovak Republic, Dept. ofMicrobiology, National 
Cancer Institute, Bratislava, Slovak Republic, National Reference 
LPboratory for Mycosis, Res. Inst. Rn! Med., Bratislava, Slovak Republic 
Twelve cancer patients with fungemia during empiric therapy with 
intravenous amphotericin B within 6 years are analyzed for etiology, 
risk factors, complications and outcome. Most common organism 
was Candida albirons in 9 and Cptococnrs laurentii, Fusarium d i m m m  
-1 Breakthrough Fungemia During ltraconazol 
Prophylaxis in Cancer Patients 
A. Demimvicova, S.  Spanik, K. Kralovicova, A. Kunova, 
V. Rusnakova, Y. Krupova, J. Trupl, V Krcmery, Jr.. St. Elizabeth 
Cancer Institute, Dept. ofMedicine; and Dept. oJPhrmacology, 
Bratislava, Slovak Republic, Nafl .  Cancer Institute, Dept. ofHematology 
and Dept. of Microbioloa, Brafislava, Slovak Republic, University of 
Tmava, Dept. $Medicine and Pharmacology, Znava, Slovak Republic 
Eight cases of breakthrough fungemias occurring during prophy- 
laxis with itraconazol were analyzed for risk factors, etiology and 
outcome. Two of 8 patients had infected central venous catheter, 7 
of 8 received antacids and low doses of itraconazol (200 mg daily) 
which may result to poor absorphon of the drug and breakhugh 
fungemia. Majority of 15 yeasts received &om 8 patients were 
Non-Candida spp. - Trichosporon pullulans (6), Cryptocom laurentii 
(2), Tomlopsis glabrata (2). Three of eight patients with breakthrough 
fungemia died, one with Candida albicans, one with Cryptoroaus lau- 
rentii and one due to Trichosporon pullulans fungemia. Amphotericin 
B or fluconazol for 13 to 71 days were administered and 5 of 8 
patients were cured. 
I P1351 I Fungemia in Patients Receiving Chemotherapy 
in a Oncology Unit 
S. S p m ,  E. Oravcovi, P. Pich6a, A. Kunovb, J. Trupl, I? Koreii, 
M. Studeni, L. Drgofia, A. Krchnikovi, E. Kukutkovb, 
V Krtmery, Jr., A. Demitmvirovi, K. Kral’ovitovi, V. Rusnikovi. 
Department of Medin’ne, University of Tmava; Bratislaw, Slovakia, 
National Cancer Institute; Technical University I$ Bratislava; Bratislava, 
Slovakia, Sf Elizabeth k Cancer Institute, Bratislava, Slovakia 
and Fusarium solani in one patient. Six of 12 patient ded  on septic 
shock due to fungemia, the rest 6 after catheter remod and in- 
creased dose of amphotericin B were cured. Prolonged neutropenia 
in 10 of 12 and infected catheter in three may be considered as the 
cause of breakthrough fungemia. All strains of Candida albicans were 
susceptible to amphotericin B. 
I Pi353 I ltraconazole Treatment in Leukemia Patients 
with Systemic Mycosis 
H.-H. Wolf, H.U. Koch’. University Hospital, Dept. of 
Haematology /Oncology, Magdeburg, Germany, ’ University Hospital, 
Dept. $Dermatology, Erlangen, Germany 
Itraconazole is an azole effective both against yeast and aspergdlus 
species. Mostly administered as prophylaxis in leukemia patients, 
there is only a few experience in long-term therapy in the im- 
munocompromised host. 
Patient’s Characteristics: We administered itraconazole (cap- 
sule form) to 5 patients suEering h m  mycotic pneumonia, mostly 
apergdlosis, during bone marrow aplasia due to chemotherapy of 
acute myelogenous leukemia in a daily dosage 500 mg over the 
first week, followed by a 100 mg dosage tds, respectively. All pts. 
had presented with nephmtoxic or anaphylactoid adverse events due 
to amphotericin B. Therapy was continued after no rdza t ion  of 
granulocyte counts until X-ray n o r d z e d .  Median duration of itra- 
conazole treatment was 79 days, mean total dosage was 27.88 g. 
Results: Mean serum concentration ofitraconazole was 1027.8 =k 
229.2 ng/ml. A steady state was seen far over the range 500 n g / d  in 
all of the patients. Adverse events were transient elevation of hepatic 
Analysis of 58 fungemias in National Institute Center within 5 years 
showed 0.4% incidence of th is  complication in patients with neo- 
plastic disease. Overall mortality was 31.0% and attributable mor- 
tality 22.4% and was similar in the groups of Candida (C.) albi- 
cans, Non-albicans C.  spp. and Non-Candida yeasts fungemias. Ma- 
jor risk factors for development of fungemia were: broad spectrum 
antibiotic combination therapy (96.6%), catheter insertion (94.8%), 
neutmpenia (63.8%), therapy with corticosteroids (41.4%) and an- 
tibiotics (46.6%). The spectrum of pathogens showed slight preva- 
lence of C. albicans (56.9% of patients), other organisms were found 
enzymes. 
Conclusions: In patients with systemic mycosis and adverse 
events to amphotericin B itraconazole may be a useful alternative 
drug, as sufficient serum concentrations are available. 
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-1 Systemic Fungemia in Acute Leukemic Patients 
R. Fanci I ,  P. Pecile *, R .  Martinez ’, A. Fabbn 
‘Department $Hematology, Uniwnity and Care@’ Hospital, Florence, 
2Department of Bacteriology and firology, Univenity and Careggi 
Hospital, Florence, Italy 
Objectives: To evaluate the incidence of systemic fungemia in 
febrile patients with acute leukemia 
Methods: From June 1992 to June 1996,502 blood cultures were 
obtained from 205 adult febrile patients with acute leukemia in re- 
mission-induction or reinduction therapy. Specimens of blood were 
inoculated into Bactec Plus Aaerobic/F and Bactec Plus Anaero- 
bic/F vials. The bottles were placed in the instrument (Bactec 9240) 
and processed according to the recommendations of manufacturer. 
The identification of the organisms was obtained by A M S  VITEK 
and confirmed by API SYSTEM BIOMERIEUX (API ID 32 C 
and API 20 AUX). 
Results: During 384 febrile episodes, there were 141 (37%) mi- 
crobiologically documented infections; fungemia was detected in 
10% of sepsis: C. albicans in 2 patients, C. tropicalis in 10 patients 
(in three of whom there were signs of hepatocanddosis, in one of 
cutaneous lntiltraton and in one of pneumonia)C. pseudotmpicalis in 
1 patient, Rhodotomla glutinis in 1 patient. Deaths from fungal in- 
fection were 50% (36% in induction and 14% in reinduction): C. 
albicans caused death in 2 patients and C. tropicalis in 5 patients. 
Conclusions: Candidiasis remains the most hquently encoun- 
tered fungal infection in acute leukemic patients. Our data show that 
invasive infection with fungemia by C. tropicdlis is being recognized 
with increasing hquency and may be fatal in hghly immunocom- 
promised patients. The role of blood cultures in the diagnosis of deep 
invasive mycosis is supported by these data. 
P. Nicoletd ’. 
1 PI 355 I Fungal Infection in Cancer Patients 
A. Smolianskaya, N. Dmitrieva. Cancer Research Center, Kashirskoe 
shosse, 24, Moscow, 115478, Russia 
Objective: To analyse the role of mycosis as a secondary infection 
in cancer patients. 
Methods: we used cultural methods to isolate and to idenhfy the 
type of Candida. The incidence and increasing rate of fungi and their 
associations with bacterial pathogens were also controlled. 
Results: the incidence rate of Candida infection in patients was 
increasing from 8.9% in 1981 to 26% in 1995. The hquency of 
Candida spp was 19-20%, the same as that of Staphylococci spp. in 
1993-1995. Mould spp. (mostly Aspergillus spp.) were determind not 
so often. Candida albicam prevaled (50%) among Candida spp., C .  
tropicalis was found in 20.5%. C. msei - in 12.1%, C. pseudotropicalis 
and guilliermondii and C. brumptii - 3.9% each, Gotrichurn candidum 
- 3.7%. Other fungi were found very rarely. Associations of fungi 
and bacterial microflora were found in 25434% of cases, mostly in 
sputum and gynecological samples. 
Conclusions: sigmficance of fungal infections in cancer hospital 
increases fbm year to year and the conaol and monitoring of the 
treatment and prophylaxis are nesessary. 
I P1356 I AmBisome 5 mg/kg versus Conventional 
Amphotericin B (AmB) 1 mg/kg in the 
Treatment of Neutropenia Associated lnvasive 
Aspergillosis 
A.C.A.P. Leenders, S. Daenen, H. Schouten, J. van der Lelie, 
R. Herbrecht, WCJ. Hop, H.C. Hoogsteden, H.A. Verbrugh, 
S. de Marie. Department ofMedical Minobiology and Infertiow Diseaces, 
University Hospital Rotterdam, the Netherlands 
To compare the efficacy of AmBisome (liposomal AmB) to that of 
AmB in the treatment of invasive fungal dections in neuaopenic 
patients, we performed a randomized comparative multicenter study. 
A total of 106 patients were included of whch 39 were not eligi- 
ble because they did not meet the diagnostic criteria, 9 had invasive 
yeast dections and 58 had proven (n = 18) or probable (n = 40) 
invasive aspergdlosis. Of t h i s  last group 27 patients were assigned 
to AmBisome and 31 to AmB. Both groups were comparable for 
age, underlymg illness and severity of infection. Both the duration 
of neutropenia before (median 23 and 18 days resp.) and after en- 
rollment (median 5 and 7 days) did not sigmficantly dil€er. Groups 
were treated for a median of 24 and 23 days resp.. After completion 
of medication, intention to treat analysis showed that in the AmBi- 
some group 11 patients were a success, 6 improved and 9 failed as 
compared to 6, 13 and 12 patients resp. treated with AmB (success 
rate AmBisome versus AmB, P = 0.08). One patient was lost in 
follow-up. Rates of mortality pmbably attributable to the infection 
were 4/27 vs 6/31 during treatment period and 5/27 vs 11/31 dur- 
ing treatment plus follow-up (4 weeks) period. The mednn time to 
resolution of clinical signs was 7 days for patients treated with AmBi- 
some versus 17 days for patients treated with AmB ( P  = 0.11). The 
median time to improvement of chest X-rays was 14 days in both 
groups. Two patients treated with AmBisome versus 6 treated with 
AmB had to stop because of toxicity. We condude that because there 
is a trend to better c h d  response for AmBiiome, AmBisome is a 
good alternative for AmB in the treatment of invasive aspergdlosis in 
the neutropenic patient. 
I PI 357 I Direct Effects of Various Corticosteroids and 
Cytokines on Candida albicans (CA) 
J. Meletiades, S. Tsaparidou, E. Roilides. 3rd Dept Pediatrirs, U 
Thessaloniki, Grpece 
Objective: To study the effects of dexamethasone (DXS), hydrocor- 
tisone (HCS), human interleukin (IL)-lO, tumor necrosis factor4 
(TNF) and granulocyte colony-stimulating factor (G-CSF) on germ 
tube formation and hyphal metabolic activity of CA, a pathogen with 
increased morbidity and mortality in immunocompromised hosts. 
Methods: lo6 CA blastoconidia were incubated with various 
concenmtions of immunomodulators in RPMI-1640 at 37°C for 
2 h and germ tubed100 fungi (blastoconidia plus germ tubes) were 
then counted. Hyphae were produced by incubating lo5 bluto- 
conidia at 37°C for 4 h. The colorimetric M l T  conversion assay 
was used to assess metabolic activity of CA hyphae in the presence 
of various concentrations of immunomodulators for 2 h. ANOVA 
with Dunnett test was used. 
Results: In the presence of DXS (3 pg/ml), blastoconidia exhib- 
ited enhanced capacity to form germ tubes (68.8 f 6.5% vs. 59 k 
6.5% of controls, p = 0.02) whereas, in the presence of HCS (1-10 
mglml), hyphae exhlbited enhanced MTT conversion (at 10 mg/ml: 
1.4 f 0.07 OD units vs. 0.6 f 0.04 of controls, p c 0.001). IL-10 
(1-1000 ng/ml) and TNF (0.01-100 ng/ml) did not af€ea germ 
tube formation or hyphal metabolic activity. In contrast, G-CSF 
(0.01 pg/ml) caused a smal l  but sigNficant increase of hyphal activ- 
ity (0.67 f 0.05 vs. 0.54 f 0.05, p = 0.003). 
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Conclusion: HCS and G-CSF augment metabolic status of CA 
hyphae whereas DXS increases germ tube formation. These effects 
help further understanding modulation of infection with ths organ- 
ism by high concentrations of corticosteroids and unexpectedly by 
G-CSE 
1 PI358 1 Efficacy and Safety of Amphoten'cin B Lipid 
Complex (Abelecet") in Fungal Infections 
€! Clevenbergh, E Jacobs, A. Kentos, B. Byl, L. Collignon, 
M. Moerman, E. Serruys, J.P Thys. Erasme University Hospital, 
Brussels, Belgium 
Compared to amphotericin B deoxycholate (Am B), lipid-associated 
amhotericin B seems to have a reduced toxicity with a s d a r  effi- 
cacy. We present the result of 28 patients @u) treated with ABLC. 
Our pts (18 males, 10 females) were of a mean age of 45 years 
(1 5-74). Their underlying condition were: solid organ transplanta- 
tion in 9, Hematologic malignancy in 6, wide spectrum antibiotics 
in 4, and miscellaneous in 8. Fungal infection consisted in invasive 
aspergillosis (11 proven, 7 suspected), invasive candidtasis (7 proven, 
1 suspected), 1 Fusariemia, 1 cryptococcal meningitis, 1 geotrichum 
angiocholitis, and 1 dtgestive mucormycosis. Twenty one pts, ini- 
tially treated with Am B, were shifted to ABLC because of clinical 
failure in 4, nephrotoxicity of Am B alone or in combinadon with 
other drugs in 15, and acute side effects in 2. Eight pts received 
ABLC as first line therapy because of concomitant use of nephm- 
toxic drugs. Initial dose of ABLC was 5 mg/kg/d with a mean 
cumulative dose of 6107 mg (600-16,000) in a mean duration of 22 
d (4-49). Clinical response rate was 63% (19/30) with mycological 
eradication in 41% (7/17). For proven aspergdosis, correspondmg 
rates were 54% (6/11) and 20% (2/10), and in proven candidiasis 
71% (5/7) and 60% (3/5), respectively. Six deaths were due to pro- 
gression of fungal dtsease, 4 to underlying diseases, and 1 remained 
unclear. Twenty one course were complicated by one or more side 
effects: fever and chills ( l l) ,  degradation of renal function (15130) 
requiring a transient reduction of drug dosage, hypotension (1). No 
death was ataibutted to the drug. Creatinin clearance before, after 2, 
4, and 6 weeks of treatment remained quite stable. We conclude that 
ABLC is well tolerated in pts with altered renal function in whom it 
could be proposed as the first line therapy for invasive mycosis with 
an efficacy similar to that of Am B. 
I PI359 I Liposomal Amphotericin B in the Treatment of 
Fungal Infections in lmmunocompromised 
Cancer Patients 
C. Lequaghe, G. Giudice, PI? Brega Massone. Oncologic Thoracic 
S u g q ,  Istituto Nazionale Turnon', Milano, Italy 
Pulmonary fungal infection is a serious and fkquent oppormnis- 
tic disease in immunocompromised cancer patients. Eight patients 
with thoracic malignancies developed pulmonary fungal dections 
during post-operative period or chemo-radtotherapy induced neu- 
tropenia. All patients were recovered in ICU, and for various causes 
reported serious immunosuppression. All patients were treated with 
fluconazole waiting for mycological response. Five cases had inva- 
sive aspergllosis and three deep candidosis. The infection was re- 
vealed by BAL, blood culture, and CT scan of chest. After myco- 
l o g 4  response we administered liposomal amphotericin B (Am- 
Bisome), because the previous therapy failed. The administetion 
protocol of Ambisome was: 1.5 mg/kg/die iv for 15 days. Two 
patients were treated also with human recombinant granulocyte 
colony-stimulating factor for serious neutropenia. Two patients re- 
ceived antifungal therapy after esophago-gastric resection for can- 
cer complicated with anastomotic fistula. One other patient with a 
smal l  cell lung cancer, during chemo-radioterapy, revealed a com- 
plete response, but TC showed a pericardic effusion and a sublo- 
bar mass. The operative specimen showed a pulmonary aspergillosis. 
The targeting treatment with liposomal amphotericin B resolved the 
residual fungal disease. The last 3 cases, all emphisematous men, 
after lobectomy showed an opportunistic infection of candida trop- 
icalis. The fungal dection was debated after the administration of 
liposomal amphotericin B. In all cases the choice of andimgal ther- 
apy did not cause serious side effects, due iv administration, like 
thrombophlebitis, or nephrotoxicity or hepatic disfunction. In con- 
clusion, liposomal amphotericin B was a safe and effective treatment 
in opportunistic fungal infections in immunocompromised cancer 
patients. 
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Child after Thymectomy: Peculiarity of His 
Diseases 
A. b y t e  I ,  R. Versockiene I ,  D. Characejus ', M. Kazlauskaite *. 
Lithuania 
Background Experimental ablation of gl. thymus in newborn ani- 
mals disturbs infective specific immunity and immunity against mu- 
tagenicly changed cells. We did not find in literature any data related 
to gl. thymus extirpation in human newborn. Subject: We present 
a report of 2 year follow-up of a child, who has gl. thymus com- 
pletely removed when he was 21 day old. The newborn was operated 
under suspicion of neuroblastoma mediastini, which was later hysto- 
logicaly recognised as hyperplastic gl. thymus. In addition, the child 
has geneticly confirmed Pierre-Robin anomaly and multiple minor 
dysplasias. 
Method: The patient was clinically observed and his immuno- 
logical status assayed by flow cytometric method. 
Results: During 2 years the child had been ill with meningitis 
purulenta (at age of 1 month), aspiration pneumonia (at 4 months), 
otitis catarrhalis (at 6 months), bronchopneumonia (at 6.5 months), 
bronchitis (at 9 months) and 7 times common dections of u p  
per respiratory tract. Anemia was diagnosed as well. Immunological 
examination shoved significant decrease of CD4 cells along with 
normal number of lymphocytes. 
Conclusion: The course of infections was characterised as slow, 
mostly without temperature (or it was subfebrile and short-term), 
without remarkable blood response. 
Centerfor Pediatricc, I.rilniW Uniuersity, Lithuania, Oncology Center, 
I PI361 1 Treatment of a Multiresistant Staphylococcus 
epidennidis Infection with 
Quinupristin/Dalfopn'stin (RP 59500) 
E. Mundlein I ,  H. von Baum', M. Springsklee 3, K. Andrassy I .  
'Intnnal Medicine, University Hospital Heidelbeg, Germany, 'Medical 
Microbiology, University Hospital HeideZbeg, Germany, 'Rho"ne-Poulenc 
Rorer, Cologne, Germany 
Case Report: A 45 year old male patient with end stage renal di- 
ease underwent kidney transplantation. A severe rejection occurred 
necessitating the explantation of the allograft. Subsequently, he de- 
veloped severe septicemia associated with respiratory failure. Exten- 
sive microbiological investigations were pefiormed but no pathogens 
could be detected except a multiresistant S. epidermidis growing in 
a single blood culture. The patient received various treatment regi- 
